Mike Hollan

Pharma products face unique issues related to chain-of-custody and cold chain.

In the final part of his conversation with Pharmaceutical Executive, Aravo CCO Dave Rusher discusses the various regulatory updates around the world in the pharma and AI space.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

While digital clinical trials provide more opportunity, they also present unique challenges that can significantly impact the trial results.

The ruling places a hold on any decisions made by the council, although the government does plan to appeal the ruling.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vivalink’s CEO Jiang Li, PhD, discusses the importance of including as much information with clinical data as possible.

Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

Ron Wyden led 7 Democrats demanding details from Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly.

The deal comes after Novo took legal action against Hims to prevent the company from offering compounded GLP-1 medications.

The vaccine chief briefly left the role last summer before almost immediately returning to it.

Pharma companies choosing between Salesforce and Veeva’s CRM has larger implications than many expect.

The drug is part of the Commissioner’s National Priority Review Voucher program.

In the second part of his conversation with Pharmaceutical Executive, Ajna Biosciences CEO Joel Stanley explains the complexities of getting a botanical drug approved.

Alice Valdur Curran discusses how the industry continues to strategize around this complicated order.

Ajna Biosciences CEO Joel Stanley discusses the differences between botanical drugs and botanically-derived drugs.

Gilead’s VP of marketing and US HIV prevention discusses the new advertising campaign for Yeztugo.

Otsuka America’s president and CEO discusses being the first major pharma company to invest in psychedelics.

In the final part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses the challenges that pharma faces when marketing direct-to-consumers.

In the second part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses how pharma marketing teams decide who to target with advertising campaigns.

Starting next January, the list prices for three of the company’s weight-loss medications will reduce.

Sandy Donaldson discusses how pharma companies are developing precise marketing strategies for the modern world.

Immuto’s CEO discusses the benefits of SPCs for target discovery.

The judges ruled against tariffs levied using an emergency law.

The vaccine advisory committee’s meeting has yet to be rescheduled.

Study results showed that patients saw three years of remission while taking the medication.

As the pharma industry continues to experiment with AI implantation, certain areas are showing more promise than others.